Quality of life (QOL) and toxicity among patients in CALGB 80405.

摘要: 3611 Background: CALGB 80405, a phase III trial, was originally designed to compare toxicity and overall survival of metastatic colorectal patients treated with standard chemotherapy (choice FOLFOX or FOLFIRI) either: 1) Bevacizumab; 2) Cetuximab; 3) both Bevacizumab Cetuximab. Because Cetuximab causes prominent acneiform skin rash, adverse effects on QOL were anticipated assessed in companion. Methods: The companion enrolled the first 518 consenting randomized 80405 between 10/2005-9/2007, majority prior amendments that eliminated dual biologic arm restricted participation KRAS wttumors. at baseline, 6 weeks, 3, 9 months post-randomization, using EORTC QLQ-30 Dermatology-Specific Quality Life (DSQL) Scale. We hypothesized receiving would have lower satisfaction appearance, reduced social functioning 3 months, (a primary assessment ...